Analysis of the electron-stream effect in patients treated with partial breast irradiation using the 1.5 T MR-linear accelerator

C. De-Colle, M. Nachbar, D. Mönich, S. Boeke, C. Gani, N. Weidner, V. Heinrich, J. Winter, S. Tsitsekidis, O. Dohm, D. Zips, D. Thorwarth

Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany
Section for Biomedical Physics, Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen, Tübingen, Germany
German Cancer Consortium (DKTK), Partner Site Tübingen, Heidelberg, Germany
German Cancer Research Center (DKFZ), Heidelberg, Germany

Abstract

Introduction: The hybrid magnetic resonance linear accelerator (MRL) has the potential to test novel concepts in breast cancer patients such as daily MR-guided real-time plan adaptation. Before starting clinical trials, preparatory studies for example of the MR-dependent electron stream effect (ESE) are necessary.

Material and Methods: To prospectively investigate the ESE, data from 11 patients treated with partial breast irradiation (PBI) at the 1.5 T MRL were evaluated. A bolus was placed on the chin and in vivo dosimetry results were compared with the dose simulated by the treatment planning system (TPS). The same measurements were carried out for three patients treated at a conventional linac. Toxicity and cosmesis were evaluated.

Results: Median doses measured and simulated on top/underneath the bolus were 1.91 / 0.62 Gy and 2.82 / 0.63 Gy, respectively. Median differences between calculations and measurements were 0.8 Gy and 0.1 Gy. At the conventional linac, median measured doses on top/underneath the bolus were 0.98 and 1.37 Gy. No acute toxicity exceeding grade 2 was recorded. Cosmesis was good or excellent and patient reported outcome measures were mostly scored as none or mild.

Conclusion: The dose due to the ESE is low, correctly predicted by the TPS and effectively minimized by a bolus.

© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
patient reported outcomes (PROMs) and cosmesis are reported. Furthermore, we examine on phantoms which factors might affect the ESE.

2. Material and methods

2.1. Patient inclusion criteria, treatment planning workflow and follow up

Eleven patients with low risk breast cancer were consecutively treated with PBI at the 1.5 T MRL Unity (Elekta AB; Stockholm, Sweden). Data were collected prospectively as part of a phase 2 feasibility study (NCT04172753, 659/2017BO1). All patients signed informed consent. Definition of low risk (“suitable group”) was based on the GEC-ESTRO [28] and the updated ASTRO criteria [29]: patients older than 50 years with unicentric, unifocal invasive not lobular breast cancer without extensive intraductal component, without lymphovascular invasion and resected with a minimum of 2 mm. Patients with tumours larger than 2 cm and hormone negative (according to ASTRO guidelines), DCIS (according to GEC-ESTRO and, partially, ASTRO guidelines), Her2 positive, with proliferation index greater than 25% and Grade 3 were excluded. Only patients with clips in the tumour bed were enrolled. PBI at the conventional linac was performed with volumetric modulated arc radiotherapy (VMAT) using cone beam computed tomography (CBCT) for daily position verification according to our institutional standard.

Patients received on the same day the planning CT (Brilliance Big Bore, Philips, Eindhoven, The Netherlands) and the planning MR (1.5 T Unity MRL, Elekta, AB, Stockholm, Sweden) in supine position with the wing board device and free breathing. A rigid automatic registration with, if needed, manual modification was used. Target definition and fractionation schedule were based on the IMPORT LOW protocol [9], as previously described [27]. Briefly, the clinical target volume (CTV) was defined including the surgical clips, the seroma, the visible tumour bed as well as the postoperative architectural changes of the surrounding breast gland, without additional margins. The planning target volume (PTV) was created adding 10 mm radial margin, limited to 5 mm from the skin surface and 7 mm posteriorly, according to the standard of our institute for PBI at the conventional linac. Ipsilateral and contralateral breast, heart, ventricles, left coronary artery, right coronary artery (according to [30]) and the lungs were considered organs at risk. The prescribed dose was 40.05 Gy (ICRU) in 15 fractions. Step and Shoot IMRT plans for the MRL were created using Monaco 5.4 (Elekta AB, Stockholm, Sweden). For all patients, a back-up VMAT plan for the conventional linac (Beam Modulator, Elekta AB, Stockholm, Sweden) was generated using our in-house treatment planning system Hyperion (Hyperion Version 4.13). For all fractions, treatment plans were adapted based on the MR of the day. Before and during treatment delivery, the organ motion was monitored with real-time MR-imaging (motion monitoring during “beam-on”), using the PTV as reference volume. Workflow of PBI planning and treatment at the 1.5 T MRL is shown in Supplementary Fig. 1. The first clinical follow up visit took place three months after treatment, then one year after treatment. Acute toxicity was scored by the treating physician according to CTCAE V4 and cosmesis results were scored on a three point scale as excellent, good or poor. In addition, PRO-CTCAE-questionnaires [31] were collected weekly during treatment and one year after, each item was scored on a five point scale, namely none (0), mild (1), moderate (2), severe (3) and very severe (4). One year after treatment, patients were asked to complete additional PROM questionnaires, namely Body Image Scale (BIS), EORTC QLQ-C30, EORTC QLQ-B23, FACT-F, and FACT-B. Items of the FACT-F and FACT-B were scored in accordance to the PRO-CTCAE on a five point scale. Items of the BIS, EORTC QLQ-C30 and QLQ-B23 were scored on a four point scale, namely not at all (1), a little (2), quite a bit (3) and very much (4). In the analysis of the PROMs, we considered for all the questionnaires a score of 3 or 4 relevant.

2.2. Electron stream effect evaluation

Based on previous publications [21–23] demonstrating in low-field and phantom measurements that the MR-specific ESE results in an out-of-field dose of the chin, we placed a 1 cm bolus (Unger Medizintechnik GmbH Co. KG, Mülheim-Köhlh, Germany) on the chin area. Since the ESE was shown to be a phenomenon that deflects electrons scattered from the high dose region into air in the direction of the magnetic field, the bolus has been positioned horizontally in cranio-caudal direction with respect to the high dose region (Fig. 1). In vivo dosimetry was performed during one treatment fraction using Grafchomic® EBT3 (Grafchomic, Ashland Specialty Ingredients, NJ, USA) films which were positioned on top and underneath of the bolus. Films were 2x5cm² large and placed in correspondence of the areas of expected higher ESE dose according to Monaco® calculations. As previously described [27], the measured dose was averaged in an area of 1.5 × 4 cm² of the radiochromic films. The simulated dose was calculated in the TPS on top and underneath the bolus using a margin of 3 mm thickness (corresponding to the dose grid resolution). The simulated dose was averaged in an equivalent area of the highest scoring dose voxels. Results of the in vivo dosimetry and the simulated dose were compared using the Wilcoxon signed rank test. For comparison with CB-CT position verification, in vivo film dosimetry was performed in three patients treated with PBI at the conventional linac (Synergy, Elekta AB, Stockholm, Sweden), the same way we performed dosimetry at the MRL, namely during one fraction with a bolus placed on patients chin and films placed on top and underneath the bolus (here the measured dose represents a sum of dose scattered by the chin and dose from the CB-CT). PBI treatments at the conventional linac were performed with 6 MV VMAT with two half arcs (e.g. from 0 to 180° and back, depending on patients anatomy and tumour location). Regarding the CBCT protocols, for right breast: start 20°, stop 180°, 120 KV, 366 frames, 585.6 mAs, nominal dose 12 mCy. For left breast: start 340°, stop 180°, 120 KV, 366 frames, 585.6 mAs, nominal dose 12 mCy.

2.3. Phantom plans comparison

The aim of this investigation was to study the ESE in different geometrical scenarios: position and volume of the breast as well as target position within the breast. For this, we used the Rando Alderson Phantom (Radiology Support Device, Long beach, CA, USA) and artificial breast prosthesis with different size (130 and 275 ml; Mesmo Sensitive/ POLYtxt, Opticon, Sublime line, Polychetic Health & Aesthetics GmbH, Dieburg, Germany). To test if the breast position, and not only the breast volume, has an impact on the dose to the chin, three different planning CTs and planning MRs were performed: 1. 130 ml- prosthesis in a caudal position, 2. 275 ml-prosthesis in a caudal position and 3. 275 ml-prosthesis in a cranial position. To test if the tumour location has an impact on the dose to the chin, we contoured for each of the three scenarios a central and a lateral located target. CTV was defined as a circle of 23 mm diameter and PTV obtained as for patients treatment (10 mm in all direction, but 7 mm posteriorly and 5 mm distant from the skin). Plans for each breast volume and position and tumour location were created with Monaco 5.4 and the dose to the chin in the presence of the magnetic field was calculated.
3. Results

Patient, tumour and treatment characteristics are summarized in Table 1. Step and Shoot IMRT plans with five to seven segments per beam were used. Treatment plans calculated with the TPS Monaco showed in all patients out-of-field dose spots in the chin area or the upper arm. Mean doses, for the sum of all 15 fractions and 40.05 Gy PTV dose, measured on top and underneath the bolus were 2.69 ± 1.95 SD and 0.56 ± 0.39 Gy, respectively (Table 2). Mean values calculated with the TPS on top and underneath the bolus were 3.11 ± 1.29 and 0.63 ± 0.25 Gy, respectively (Table 2). There was a good concordance between calculated and measured values, namely a mean difference on top of the bolus of 0.42 ± 1.08 Gy and underneath the bolus of 0.07 ± 0.45 Gy (Table 2, supplementary Fig. 2).

At the conventional linac median doses for the three patients measured on top and underneath the bolus were 0.98 Gy (range, 0.75–1.17 Gy) and 1.37 Gy (range, 0.9–1.62 Gy), respectively (Table 3).

The TPS showed in three patients with laterally located tumours an out-of-field dose as well at the arm. The median calculated doses were 2.2 Gy (range: 0.76–3.3 Gy) and 0.45 Gy (0.45–0.48 Gy) on top and underneath the bolus placed at the arm (Table 3 and Fig. 2).

Table 1

| Patient | Laterality | Tumour location | T stage | Grade | Ki67 (%) | Mean in-room time (range, minutes) | Acute toxicity | Toxicity 3 months | Toxicity 1 year | Cosmesis 1 year |
|---------|------------|----------------|---------|-------|----------|-----------------------------------|---------------|-------------------|---------------|-----------------|
| #1      | right      | upper lateral  | pT1c    | 1     | 5        | 33.5 (25–44)                      | G1 breast edema, erythema, warm feeling, pain and fatigue | G1 breast edema | G1 breast edema | good           |
| #2      | left       | upper central  | pT1c    | 2     | 5–10     | 26.2 (20–38)                      | G1 erythema and fatigue | none            | none           | excellent       |
| #3      | left       | upper lateral  | pT1c    | 1     | 10       | 26.9 (20–41)                      | G1 erythema, warm feeling and pain | G1 breast edema | G1 breast edema | good           |
| #4      | right      | lower medial   | pT1c    | 2     | 5        | 26.3 (20–32)                      | G2 breast edema, G1 erythema, warm feeling, pain and fatigue | G1 hyperpigmentation | G1 hyperpigmentation | good           |
| #5      | right      | upper medial   | pT1c    | 2     | 20       | 22.8 (19–29)                      | G1 erythema, warm feeling and pain | G1 hyperpigmentation | G1 hyperpigmentation | good           |
| #6      | right      | upper central  | pT1a    | 1     | 10       | 23.9 (21–33)                      | G2 breast edema, G1 erythema, pain and fatigue | G1 hyperpigmentation | G1 hyperpigmentation | excellent       |
| #7      | right      | upper lateral  | pT1c    | 2     | 5–10     | 22.9 (19–29)                      | G1 erythema | G1 erythema | G1 fibrosis | excellent       |
| #8      | left       | lower medial   | pT1b    | 2     | 15–20    | 25.1 (19–31)                      | G1 erythema, warm feeling, pain and fatigue | G1 hyperpigmentation, fibrosis and fatigue | none            | excellent       |
| #9      | right      | upper lateral  | pT1c    | 1     | 5        | 23.5 (19–26)                      | G1 erythema and warm feeling | none            | none            | good           |
| #10     | left       | upper central  | pT1c    | 2     | 15–20    | 25.1 (20–33)                      | G1 erythema, warm feeling and pain | G1 edema; exanthema, in few days resolved | none            | excellent       |
| #11     | left       | upper medial   | pT1c    | 2     | 10       | 27.3 (20–52)                      | G1 erythema, warm feeling and fatigue | none            | none            | excellent       |

Fig. 1. 3D reconstruction of the bolus position on patients chin.
Cosmetic outcomes one year after radiotherapy were scored as none or mild by 88.1%, 90.8%, 91.5% and 93% at week 7% of missing data, items of the PRO-CTCAE questionnaire were scored as good in five patients and excellent in six patients. Importantly, the skin reactions were located only in the high-dose irradiation field of the treatment. There was no grade 1 erythema at all. Interestingly, one patient experienced grade 1 and two patients grade 2 toxicity at the end of the treatment. Doses measured with the in vivo dosimetry for the 3 patients treated at the MRL.

| Patient | Dose measured on top of the bolus on chin (Gy) | Dose measured underneath the bolus on chin (Gy) | Absolute difference underneath the bolus on chin (Gy) | Absolute difference underneath the bolus on chin (Gy) |
|---------|-----------------------------------------------|-------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| #1MRL  | 1.76                                          | 0.51                                            | 2.70                                              | 0.68                                              |
| #2MRL  | 1.31                                          | 1.01                                            | 0.53                                              | 0.29                                              |
| #3MRL  | 1.25                                          | 1.40                                            | 1.03                                              | 0.51                                              |
| #4MRL  | 6.60                                          | 0.30                                            | 5.20                                              | 0.30                                              |
| #5MRL  | 1.20                                          | 0.86                                            | 2.31                                              | 1.25                                              |
| #6MRL  | 2.43                                          | 0.00                                            | 2.44                                              | 0.54                                              |
| #7MRL  | 3.15                                          | 0.11                                            | 4.71                                              | 0.52                                              |
| #8MRL  | 1.38                                          | 0.81                                            | 2.94                                              | 0.83                                              |
| #9MRL* | 0.41                                          | 0.00                                            | 5.53                                              | 0.28                                              |
| #10MRL | 5.81                                          | 0.09                                            | 4.48                                              | 1.02                                              |
| #11MRL | 2.06                                          | 0.72                                            | 2.70                                              | 0.36                                              |
| mean   | 2.69                                          | 0.56                                            | 3.11                                              | 0.63                                              |
| Stand. Dev.* | 1.95 | 0.39 | 1.29 | 0.25 |
| Median* | 1.91 | 0.62 | 2.82 | 0.53 |
| IQA*   | 1.6   | 0.69 | 2.07 | 0.4   |

The phantom simulation showed a higher chin dose when the target was located medially. A median dose on top of the bolus of 1.35 Gy (range, 0.49–1.6 Gy) for lateral targets and 3.66 Gy (range, 1.71–4 Gy) for medial targets was calculated. Doses were minimized by the bolus to a median value of 0.14 Gy both for lateral (range, 0.1–0.2) and medial (range 0.13–0.32 Gy) targets (Table 4).

Regarding feasibility, a total of 162 fractions were delivered at the 1.5 T MRL. In one patient, two fractions were performed at the conventional linac and doses calculated by Monaco for the 3 patients with out-of-field dose on the arm treated at the MRL.

| Patient | Dose measured on top of the bolus on chin (Gy) | Dose measured underneath the bolus on chin (Gy) |
|---------|-----------------------------------------------|-------------------------------------------------|
| #1conv.lin. | 0.98 | 0.9 |
| #2conv.lin. | 1.17 | 1.62 |
| #3conv.lin. | 0.75 | 1.37 |
| median | 0.88 | 1.37 |
| Patient | Dose calculated on top of the bolus on arm (Gy) | Dose calculated underneath the bolus on arm (Gy) |
|---------|-----------------------------------------------|-------------------------------------------------|
| #3MRL  | 0.76                                          | 0.48                                            |
| #7MRL  | 3.3                                           | 0.45                                            |
| #8MRL  | 2.2                                           | 0.45                                            |
| median | 2.2                                           | 0.45                                            |

4. Discussion

In this study, ESE was investigated in eleven patients treated with PBI at the 1.5 T MRL. ESE with out-of-field-dose to the chin potentially represents a particular challenge for PBI at the 1.5 T MRL because of the target location, i.e. a convex superficial region. Malkov et al. [23] studied factors influencing ESE using a phantom and a water panel with different surface inclinations (10, 30 and 45°), magnetic field conditions (0, 0.35 and 1.5 T) as well as distance from the isocenter. Higher doses up to 39% were measured when surfaces were more inclined and, surprisingly, with lower magnetic field strengths. The lower doses with 1.5 T were explained by the larger radius of curvature of the electron trajectories in the 0.35 T. Moreover, even though a higher out-of-field-dose was measured when the panel was closer to the isocenter, the difference was very small, without revealing a large variation of the ESE dose. Interestingly, even at 0 T an up to 9% out-of-field-dose was detected. Furthermore, a good agreement between the Monte Carlo simulated out-of-field ESE dose and the EBT-3 film measurements on phantoms were observed [24]. Similarly, good accordance of simulated and measured dose was reported for the electron return effect [33].

MR guided PBI has been clinically performed in low-field MRL [34,35] and the ESE has been documented in this setting [21]. We have performed the first-in-human PBI treatment at the 1.5 T MRL [27] and documented an ESE in this first patient. As the ESE has not been systematically evaluated for 1.5 T, the present study aims to prospectively characterize the ESE in a group of consecutive patients resembling interpatient heterogeneity in anatomy.
and target position. This study was designed as a preparatory trial for future clinical trials testing novel concepts at the 1.5 MRL. Overall, our data suggest the ESE to the chin is low (and comparable to CB-CT based PBI), correctly predicted by the TPS and efficiently prevented by a 1 cm bolus. Minimizing radiation dose to normal tissues is of particular importance for breast cancer patients because these patients have an excellent oncological outcome and may experience very late side effects. Although with a very limited follow-up and patient number, physician and patient reported outcome measurements indicated that the PBI at the 1.5 T was well tolerated.

The phantom measurements indicated that geometric factors may influence the magnitude of the ESE to the chin: higher doses were documented when the target was located medially, while breast size had no impact on ESE dose to the chin. In line with Malakov et al. [23], cranio-caudal position of the target did not affect ESE. In addition, TPS simulations in our study revealed that lateral targets might result in a ESE dose to the arms which again can be minimized by a 1 cm bolus.

Our study has a number of limitations. First, it suffers from inherent inaccuracies of the methods including in vivo dosimetry and low dose simulation in TPS. Geographical mismatch of the area used for in vivo dosimetry and dose simulation might further limit the comparison of the read-out parameters. The impact of this uncertainty on the results of our study is aggravated by the fact that only one film measurement was performed per patient and therefore no information on intra-patient reproducibility could be obtained. Instead, the study was designed to evaluate inter-patient variability of the ESE. Second, the number of patients is small and follow-up is very limited. Given the fact that only a small number of patients can be treated at the MRL at a given time, an external validation of our early and limited observations would be of great value. Nevertheless, we feel that our data might give important information for the safety of patients and the design of future interventional trials in breast cancer using the 1.5 MRL. Of note, the phantom analysis was performed to study geometric effects and only calculated doses were used in this part of the study.

Our initial experience with regard to the MR daily adaption procedure, in-room-time and feasibility suggest that the 1.5 MRL appears to be suitable to test novel treatment concepts in breast cancer patients, i.e. neoadjuvant MR-guided radiotherapy. The dosimetric results may lead to protocol recommendations to manage ESE in such trials.

**Table 4**

| Phantom       | Dose calculated on top of the bolus on chin (Gy) | Dose calculated underneath the bolus on chin (Gy) |
|---------------|--------------------------------------------------|--------------------------------------------------|
| Small Breast lateral | 0.49                                              | 0.1                                              |
| Small Breast medial  | 1.71                                              | 0.13                                             |
| Large Breast lateral  | 1.6                                               | 0.14                                             |
| Large Breast medial    | 3.66                                              | 0.14                                             |
| Large High Breast lateral | 1.35                                              | 0.2                                              |
| Large High Breast medial | 4                                                 | 0.32                                             |
| Median lateral       | 1.35                                              | 0.14                                             |
| Median medial        | 3.66                                              | 0.14                                             |

**Fig. 2.** Example of out-of-field dose on the arm for a patient with lateral located tumour. Left the PTV in green and the isodoses are shown, in orange the 95% isodose (region of interest and isodose legend displayed in the figure). Upper left: sagittal, lower left: coronal image. Lower right a three dimensional reconstruction of the patient, including ipsilateral, contralateral breast, PTV and bolus on the right arm is shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Declaration of Competing Interest

The MR-Linac research program is funded by the German Research Council (to D.T. and D.Z., ZI 736/2-1). Radiation Oncology Tübingen receives financial and technical support from Elekta AB (Stockholm, Sweden) under a research agreement. C.D.C. is supported by the Medical Faculty Tübingen (TUFF).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ctro.2020.12.005.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34.
[2] Mannino M, Yarnold J, Accelerated partial breast irradiation trials: diversity in rationale and design. Radiother Oncol 2009;91(1):16–22.
[3] Salvadori B, Marubini E, Miceli R, Conti AR, Cusumano F, Andreola S, et al. Reoperations for locally recurrent breast cancer in patients previously treated with conservative surgery. Br J Surg 1999;86(1):84–7.
[4] Hattangi JA, Powell SN, MacDonald SM, Maurer T, Anczkiewicz M, Feer P, et al. Accelerated partial breast irradiation with local dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys 2012;83(3):791–800.
[5] Polgar C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017;18(2):259–68.
[6] Wilkinson JB, Betsch PD, Shah C, Arthur D, Haffty BG, Wazer DE, et al. Evaluation of current consensus statement recommendations for accelerated partial breast irradiation: a pooled analysis of William Beaumont Hospital and American Society of Breast Surgeon Mammorad Registry Trial Data. Int J Radiat Oncol Biol Phys 2013;85(5):1179–85.
[7] Veronesi U, Orecchia R, Maisonneuve P, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol 2012;13(13):1269–77.
[8] Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 2014;383(9917):603–13.
[9] Coles CE, Griffin CL, Kirby AM, Tiley J, Agraval RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017;389(10099):1048–60.
[10] Interdisziplinäre S3-Leitlinie fuer die Frueherekennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2017:144.
[11] Cardoso FKS, Ohno S, Pelusin-Pirola F, Poortmans P, et al. Early breast cancer: ESRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019.
[12] TRCOn FoCo. Postoperative radiotherapy for breast cancer: UK consensus statements. 2016:22–3.
[13] Werensteijn-Honingh AM, Kroon PS, Winkel D, Aalbers EM, van Asselen B, Bol GH, et al. Feasibility of stereotactic radiotherapy using a 1.5T MR-linac: multifraction treatment of pelvic lymph node oligometastases. Radiat Oncol 2019;14:50–4.
[14] Murray J, Tree AC. Prostate cancer - advantages and disadvantages of MR-guided RT. Clin Transl Radiat Oncol 2019;18:68–73.
[15] Cani C, Boldrini L, Valentini V, Online MR guided radiotherapy for rectal cancer. New opportunities. Clin Transl Radiat Oncol 2019;18:60–6.
[16] Chiloio G, Boldrini L, Moldolesi E, Re A, Cellini F, Cusumano D, et al. MR-guided radiotherapy in rectal cancer: first clinical experience of an innovative technique. Clin Transl Radiat Oncol 2019;18:60–6.
[17] Finazzi T, Palacios MA, Haasbeek CJA, Admiraal MA, Spoelstra FOB, Bruyneel AME, et al. Stereotactic MR-guided adaptive radiation therapy for peripheral lung tumors. Radiat Oncol 2020;15:40–52.
[18] Paulson ES, Ahnabey F, Chen X, Miekkevicus NJ, Chen G-P, Schultz C, et al. 4D-MRI driven MR-guided online adaptive radiation therapy for abdominal stereotactic body radiotherapy on a high field MR-Linac: implementation and initial clinical experience. Clin Transl Radiat Oncol 2020;23:72–5.
[19] Dunlop A, Mitchell A, Tree A, Barnes H, Bower L, Chick J, et al. Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clin Transl Radiat Oncol 2020;23:35–42.
[20] Groot Koorckamp ML, Vasmel JE, Russell NS, Shaitelman SF, Anandadas CN, Cunney A, et al. On behalf of the breast tumor site group of the international MR-linac atlantic consortium. Optimizing MR-guided radiotherapy for breast cancer patients. Front Oncol 2020;10:1107. https://doi.org/10.3389/fonc.2020.01107.
[21] Park JM, Shin KH, Kim J-Y, Park S-Y, Jeon SH, Choi N, et al. Air-electron stream interactions during magnetic resonance IGRT: skin irradiation outside the treatment field during accelerated partial breast irradiationLuft-Elektronenstrahl-Interaktionen in der Magnetresonanztomographie-gestützten IGRT: Hautbestrahlung außerhalb des Zielgebietes während einer akzelerisierten Teilbrustbestrahlung. Strahlenther Onkol 2018;194:1:50–9.
[22] Hättig SA, van Asselen B, Wolthaus JWH, Bluemink JJ, Ishakoglu K, Jok J, et al. Spiralling contaminant electrons increase doses to surfaces outside the photon beam of an MR-linac with a perpendicularly magnetic field. Phys Med Biol 2019;64(3):035001. https://doi.org/10.1088/1361-6560/aab6a6.
[23] Malkov VN, Hackett SL, Wolthaus JWH, Raaymakers BW, van Asselen B. Monte Carlo simulations of out-of-field surface doses due to the electron streaming effect in orthogonal magnetic fields. Phys Med Biol 2019;64(11):113029. https://doi.org/10.1088/1361-6560/aab6a6.
[24] Malkov VN, Hackett SL, van Asselen B, Raaymakers BW, Wolthaus JWH. Monte Carlo simulations of out-of-field skin dose due to spiralling contaminant electrons in a perpendicularly magnetic field. Med Phys 2019;46(3):1467–77.
[25] Kim A, Lim-Reinders S, McCann C, Ahmad SB, Sahgal A, Lee J, et al. Magnetic field dose effects on different radiation beam geometries for hypofractionated partial breast irradiation. J Appl Clin Med Phys 2017;18(6):62–70.
[26] Richter SFS, Mönich D, Dohnin OS, Thorwarth D. Influence of a transverse magnetic field on the dose deposited by a 6 MV linear accelerator. Curr Direct Biomed Eng 2017;3:281–5.
[27] Nachbar M, Monnich D, Boeke S, Gani C, Weidner N, Heinrich V, et al. Partial breast irradiation with the 1.5 T MR-Linac: first patient treatment and analysis of electron return and stream effects. Radiat Oncol 2019;14:30–5.
[28] Polgar C, Van Lijmenberg E, Potter R, Kovacs G, Polo A, Lyczek J, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Group Européen de Curiethérapie-Europäische Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiat Oncol 2010;5:264–73.
[29] Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol 2017;7(2):73–9.
[30] Feng M, Moran JM, Koelling T, Chuangti A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011;79(1):10–8.
[31] https://healthcareedilevery.cancer.gov/pro-ctacce.
[32] Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. Adaptive radiotherapy: the Elekta Unity MR-linac concept. Clin Transl Radiat Oncol 2019;18:54–9.
[33] Han EYWZ, Lee HJ, dela Cruz Paulino A, Lee C. Measurement of Electron Return Effect and Skin Dose Reduction by a Bolus in an Anthropomorphic Physical Phantom under a Magnetic Resonance Guided Linear Accelerator (MR-LINAC) System. Int J Med Phys Clin Eng Radat Oncol 2018.
[34] Henke LE, Contreras JA, Green OL, Cai B, Kim H, Roach MC, et al. Magnetic resonance image-guided radiotherapy (MRigRT): A 4.5-year clinical experience. Clin Oncol (R Coll Radiol) 2018;30:720–7.
[35] Acharya S, Fischer-Valuck BW, Mazur TR, Curcuru A, Sona K, Kashani R, et al. Magnetic resonance image guided radiation therapy for external beam accelerated partial-breast irradiation: evaluation of delivered dose and intrafractional cavity motion. Int J Radiat Oncol Biol Phys 2016;95(2):858–92.